Peptide Impurities Explained: Deletion Sequences, Truncations, Oxidation, and Deamidation

A purity figure looks reassuringly precise. If a peptide is reported as 99% pure, it is tempting to treat the remaining 1% as little more than background noise. In reality, that fraction can contain several chemically different species, and how they differ from the intended peptide can matter as much as the percentage itself.

For researchers working with research peptides, the more useful question is therefore not simply whether impurities are present. It is whether they arose during synthesis, appeared later through degradation, and what the analytical data can actually reveal about them.

Note: This article is provided for educational purposes within a laboratory research context only. It does not promote or suggest peptide use in humans or animals.

What Peptide Impurities Actually Are

“Peptide impurity” is a broad analytical category rather than the name of one type of substance. A sample can contain sequences that were assembled incorrectly, shortened versions of the intended peptide, chemically altered versions of an otherwise complete sequence, or several of these at the same time.

The first useful division is between synthesis-related impurities and degradation-related impurities. Deletion sequences, truncations, insertions, and some stereochemical variants usually trace back to peptide assembly. Oxidation and deamidation are different: they can alter a peptide after the intended sequence has already been formed.

That distinction becomes easier to understand when looking at how research peptides are made. In solid-phase peptide synthesis, amino acids are added sequentially to a growing chain, followed by cleavage, purification, and analytical testing. Every additional reaction step creates another point at which a small proportion of molecules can follow a different chemical path from the intended product.

Impurity Type	Typical Origin	What Changes
Deletion sequence	Synthesis	One or more intended amino acids are missing
Truncated sequence	Synthesis	The peptide chain ends prematurely
Insertion sequence	Synthesis	One or more unintended residues are present
Stereoisomer / epimer	Synthesis	Configuration changes at an amino-acid residue
Oxidized peptide	Processing or degradation	Susceptible chemical groups become oxidized
Deamidated peptide	Degradation	Amide-containing residues undergo chemical modification

The table makes the categories look tidy, but an actual impurity profile may not be. Several related species can appear together, and structurally similar peptides may also behave similarly during purification and analysis.

How Deletion Sequences Form

A deletion sequence contains most of the intended peptide but is missing one or more residues. One of the classic routes is incomplete coupling during synthesis.

Imagine that an amino acid is supposed to attach to every growing peptide chain during a particular synthesis cycle. If coupling fails on a small fraction of those chains but later reactions continue normally, the resulting molecules can reach the end of synthesis with an internal amino acid missing. Incomplete deprotection can produce a related outcome by temporarily preventing a growing chain from participating in the next coupling step.

This is what makes deletion products particularly troublesome: they can be almost right. A peptide missing one residue may still share much of the target molecule’s size, charge, hydrophobicity, and overall chromatographic behaviour.

Why “Almost Right” Can Be Analytically Difficult

The closer an impurity is to the target structure, the harder separation can become. A completely unrelated contaminant may produce an obvious chromatographic signal, while a single-residue deletion can sit much closer to the target peak.

This is also why identity and purity are not interchangeable measurements. The COA testing process treats them separately: chromatographic analysis can describe the relative composition of a sample, while mass-based analysis addresses whether the expected molecular species is actually present.

A large target-associated peak is useful information. It does not, by itself, identify every minor species surrounding it.

Truncated Peptides Are a Different Kind of Incomplete Sequence

Deletion and truncation are sometimes discussed together because both can originate during synthesis, but they describe different structures.

Take a simplified target sequence:

A–B–C–D–E

A deletion product could be:

A–B–D–E

The chain continued growing, but residue C is absent.

A truncated product might instead be:

A–B–C

Here, the chain never reached its intended final length.

That difference changes more than terminology. A short truncation product can differ substantially from the full peptide in molecular mass and chromatographic behaviour, while an internal one-residue deletion may remain comparatively similar.

Capping Can Change the Kind of Impurity That Remains

Peptide synthesis workflows can use capping reactions to block chains that failed to react during a coupling step. Once capped, those chains can no longer continue through the full sequence.

The purpose is not to make failed synthesis disappear. Instead, it can prevent an incomplete chain from continuing and becoming a near-full-length deletion product. The resulting shorter material may then be easier to distinguish during purification.

This illustrates a recurring theme in peptide analytical chemistry: the impurity profile partly reflects the chemistry used to control the synthesis itself.

Oxidation Changes the Peptide Without Shortening It

Oxidation belongs to a different category. The amino-acid chain can remain intact while one or more susceptible side chains undergo a chemical change.

Methionine is one of the best-known oxidation-sensitive residues, although cysteine, tryptophan, tyrosine, histidine, and other amino acids can also participate depending on sequence and conditions. Oxygen exposure, light, temperature, reactive species, trace metals, and the surrounding chemical environment can all influence oxidative pathways.

A peptide can therefore contain every expected amino acid in the correct order and still no longer be chemically identical to the original target.

A Small Chemical Change Can Create a New Analytical Species

This is one of the areas where mass spectrometry becomes particularly useful. Oxidation produces changes in molecular composition that can create recognizable shifts in measured mass, allowing an oxidized form to be distinguished from the unmodified parent molecule when the analytical method has sufficient resolution.

The broader point is important: sequence alone does not describe every aspect of peptide identity. Post-synthesis chemical changes can alter what an instrument detects even when the written amino-acid sequence appears unchanged.

Deamidation Can Be Even More Subtle

Deamidation most commonly draws attention to asparagine and glutamine residues. Rather than removing an amino acid, the reaction changes an amide-containing side chain into another chemical form.

With asparagine, the pathway can proceed through a succinimide intermediate and produce both aspartate- and isoaspartate-related products. That means what begins as one defined peptide can gradually develop a small family of closely related molecular species.

The presence of asparagine does not automatically mean rapid deamidation, either. Neighbouring residues, local peptide structure, molecular flexibility, pH, temperature, and solvent environment all influence susceptibility.

Chemical Stability and Biological Half-Life Are Not the Same Thing

This is where two ideas that are often grouped together need to be kept separate. Chemical degradation describes what happens to the molecule itself, while half-life describes persistence under a defined experimental measurement system.

The distinction is explored in more detail in the guide to how peptide half-life is measured. A peptide may be susceptible to a particular degradation pathway under one set of conditions without that reaction alone determining the pharmacokinetic half-life reported in a biological model.

In other words, “stable” can mean different things depending on what the experiment is actually measuring.

Synthesis Impurity or Degradation Product?

When an unexpected peptide-related species appears, one useful question is: when did the difference arise? A skipped residue, unintended insertion, or prematurely terminated chain points back toward synthesis. Oxidation or deamidation of an otherwise complete peptide points instead toward post-synthesis modification or degradation.

The distinction leaves researchers with two separate questions: Was the intended molecule assembled correctly, and did it remain chemically unchanged afterward? A complete analytical picture may need to address both, because detecting the expected molecular mass does not exclude every degradation product, while high chromatographic purity does not independently establish the identity of every detected species.

Not Every Peptide Modification Is an Impurity

There is another important distinction: a modified peptide is not automatically an impure peptide. Peptide chemistry deliberately uses terminal modifications, cyclization, conjugation, and other structural changes to create defined analogs.

The difference comes down to intent. If a modification is part of the specified target structure, it belongs to the identity of the peptide. If it appears unintentionally alongside that target, it may belong to the impurity profile.

A useful example is P-21 (Adamantane). Its adamantane group is not an accidental addition detected during testing; it is part of the defined molecular structure being studied. Analytical identity must therefore be evaluated against the modified molecule rather than against the unmodified DGGL tetrapeptide alone.

Terminal Modifications Make the Same Point

The distinction is particularly clear when comparing Epithalon and N-Acetyl Epithalon Amidate. Both retain the AEDG peptide core, while the latter deliberately adds N-terminal acetylation and C-terminal amidation.

Those terminal changes alter molecular characteristics, but they are not impurities because they belong to the specified structure of that analog. An unintended oxidized, deamidated, truncated, or deletion form appearing alongside it would be a different matter.

This is why analytical testing always needs a clearly defined target. You cannot determine whether a molecular difference is an impurity until you know exactly which molecular form the sample is supposed to contain.

What HPLC Can Reveal About Peptide Purity

High-performance liquid chromatography is one of the main tools used to examine peptide purity because it separates compounds according to differences in how they interact with the chromatographic system. A typical chromatogram may show one dominant peak alongside several smaller ones, with their relative peak areas used to estimate the proportion of chromatographically detected components.

This is where statements such as “99% HPLC purity” come from. Broadly speaking, the figure indicates that the dominant detected component accounts for about 99% of the integrated chromatographic response under the conditions of that particular method.

A Purity Percentage Belongs to a Method

HPLC does not provide a universal inventory of everything physically present in a sample. Results depend on factors such as column chemistry, mobile phase, gradient conditions, detector settings, sample preparation, peak integration, and the method’s ability to resolve closely related species.

Structurally similar impurities may separate clearly under one method but overlap under another, and some can co-elute with the target peak. Different peptide-related species may also produce different detector responses. HPLC purity is therefore best understood as chromatographic purity under defined analytical conditions, rather than as a complete description of every component in the sample.

Mass Spectrometry Answers a Different Question

If HPLC helps describe how a sample separates, mass spectrometry helps investigate the molecular identity of those species. Deleting an amino acid changes molecular mass, an unintended insertion changes it in the opposite direction, and oxidation can produce a characteristic mass shift. More advanced LC-MS/MS workflows can provide additional structural information through fragmentation patterns.

Chromatography and mass spectrometry are therefore complementary rather than competing techniques. HPLC may reveal that a minor component exists, while MS can help determine whether its molecular mass is consistent with a particular structural variant.

Identity and Purity Need to Stay Separate

This distinction matters whenever a purity number is used as shorthand for overall quality. A chromatogram may show that one component dominates, but that alone does not establish that the dominant component has the expected molecular identity.

Conversely, detecting the expected molecular mass confirms important information about identity but does not automatically quantify every related impurity in the sample.

That is why analytical documentation becomes more useful when identity, purity, and batch-specific results are read together rather than collapsed into one number.

So What Does “99% Pure” Actually Tell Researchers?

A 99% purity result provides useful information, but it does not describe the identity of every component in the remaining fraction. Two samples can carry the same reported purity while having very different minor profiles: one might contain a deletion product, another several oxidation products, and another a mixture of truncated or chemically modified species.

This is also why identity and purity need to remain separate analytical concepts. A chromatogram can show that one component dominates without independently proving its molecular identity, while detecting the expected molecular mass does not automatically quantify every related impurity.

The remaining fraction should therefore not be imagined as one anonymous contaminant. In peptide analysis, what makes up that fraction may be more informative than the simple fact that it exists.

Researchers looking across a research peptide catalog will encounter molecules with different lengths, sequences, terminal structures, and deliberate modifications. Those structural differences can influence which synthesis challenges, degradation pathways, and analytical approaches are relevant to their characterization.

Why Impurity Profiles Matter for Reproducible Research

Research depends on defined experimental inputs. If two nominally identical peptide samples contain different related species, treating them as chemically interchangeable can introduce another uncontrolled variable into the experiment.

A deletion product may retain much of the parent sequence while losing a residue important to structure. Deamidation can alter local charge. Oxidation may influence conformation or molecular interactions. A truncated peptide may differ far more substantially from the full-length target.

None of this means that every trace impurity will necessarily change an experimental outcome. It means that purity percentage alone cannot answer whether an impurity is analytically or experimentally relevant.

That question depends on what the impurity is, how much is present, what the research model measures, and whether the analytical method can distinguish the target from closely related species.

Peptide Purity Is the Beginning of the Analytical Story

A peptide chromatogram can compress a complicated chemical history into a handful of peaks and one convenient percentage. Behind those peaks, however, may be missed coupling reactions, prematurely terminated chains, oxidized side groups, deamidated residues, or other related molecular forms.

Deletion sequences and truncations tell researchers something about how the peptide was assembled. Oxidation and deamidation tell them something about what may have happened to the molecule after assembly. Deliberate structural modifications add another layer by showing why a chemical difference is not automatically an impurity at all.

That is why peptide purity is most informative when it is read alongside molecular identity and the conditions of the analytical method. Instead of stopping at “Is it 99% pure?”, the more revealing question is:

What is actually present in the remaining fraction, and what evidence allows us to identify it?

Research References

• European Medicines Agency. Guideline on the Development and Manufacture of Synthetic Peptides. EMA/CHMP/CVMP/QWP/367182/2025. First published December 9, 2025; legally effective June 1, 2026.
• U.S. Food and Drug Administration. FDA Publishes Revised Draft Product-Specific Guidances for Certain Generic Peptide Products. Published July 28, 2026.
• D’Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, De Spiegeleer B. Related Impurities in Peptide Medicines. Journal of Pharmaceutical and Biomedical Analysis. 2014;101:2–30. doi:10.1016/j.jpba.2014.06.012.
• Lian Z, Wang N, Tian Y, Huang L. Characterization of Synthetic Peptide Therapeutics Using Liquid Chromatography-Mass Spectrometry: Challenges, Solutions, Pitfalls, and Future Perspectives. Journal of the American Society for Mass Spectrometry. 2021;32(8):1852–1860. doi:10.1021/jasms.0c00479.
• Torosantucci R, Schöneich C, Jiskoot W. Oxidation of Therapeutic Proteins and Peptides: Structural and Biological Consequences. Pharmaceutical Research. 2014;31(3):541–553. doi:10.1007/s11095-013-1199-9.
• Bischoff R, Kolbe HV. Deamidation of Asparagine and Glutamine Residues in Proteins and Peptides: Structural Determinants and Analytical Methodology. Journal of Chromatography B: Biomedical Applications. 1994;662(2):261–278. doi:10.1016/0378-4347(94)00203-7.
• Kuril AK. The Critical Need for Implementing RRF in the Accurate Assessment of Impurities in Peptide Therapeutics. Analytical Chemistry. 2025;97(24):12480–12485. doi:10.1021/acs.analchem.5c02149.
• Paravizzini SJ, Haugaard-Kedström LM, Hutton CA, Karas JA. Backbone Protecting Groups for Enhanced Peptide and Protein Synthesis. Angewandte Chemie International Edition. 2025;64(33). doi:10.1002/anie.202509939.

What are the most common types of peptide impurities?

Common peptide impurities include deletion sequences, truncated sequences, insertion products, stereoisomers, oxidized species, deamidated species, and other synthesis, or degradation-related compounds. The exact profile depends on peptide sequence, synthesis chemistry, purification, handling, and environmental conditions.

What is the difference between a deletion peptide and a truncated peptide?

A deletion peptide is missing one or more intended residues while the sequence continues beyond the missing position. A truncated peptide ends prematurely because synthesis did not complete the intended chain.

Can a peptide have high HPLC purity and still contain impurities?

Yes. A high HPLC purity result means the target-associated chromatographic peak dominates under the conditions of that particular method. Some structurally related species may separate poorly or co-elute, which is one reason HPLC purity is often interpreted alongside identity testing such as mass spectrometry.

Are oxidation and deamidation synthesis impurities?

They are more commonly considered chemical modification or degradation pathways, although oxidation can also occur during manufacturing and processing. Unlike deletion and truncation, they generally modify an existing peptide rather than producing an incomplete sequence.

Is a chemically modified peptide always an impurity?

No. A modification such as acetylation or amidation may be an intentional part of the specified target structure. It becomes an impurity issue when an unintended molecular species is present alongside the compound the analytical method is intended to characterize.

Why are peptide impurities important in laboratory research?

Different impurities may have different chemical and structural properties from the intended peptide. Characterizing the material more completely can therefore help researchers define experimental inputs, compare batches, and interpret results with greater confidence.